Facebook Linkedin Soundcloud Twitter Vimeo Xing
Home Tags Progression Free Survival

Tag: Progression Free Survival

Datopotamab Deruxtecan Offers Meaningful PFS Benefit in Treatment of HR-positive,...

ADC Review | Editorial Team
The positive top-line results from TROPION-Breast01 demonstrate the potential for datopotamab deruxtecan to become an important treatment option for patients with HR-positive, HER2-low or HER2-negative breast cancer in the second-line metastatic setting.

Compared to Brentuximab Vedotin, Nivolumab Reduces Risk of Disease Progression in...

ADC Review | Editorial Team
Compared to Brentuximab Vedotin, Nivolumab Reduces Risk of Disease Progression in Untreated Hodgkin Lymphoma
ADC Review, Journal of Antibody-drug Conjugates
ADC Review, Journal of Antibody-drug Conjugates (ISSN 2327-0152) is an international peer-reviewed publication designed to serve the needs of a diverse community of individuals including academia, life sciences, pharma, research, clinicians and physicians. Along with regulatory affairs, we also cover government authorities and representatives from payers to policymakers.

Latest

Peer Review

© 2013-2020 Sunvalley Communication, LLC. All Rights Reserved.

X